Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J
If symptoms appear: Test promptly for persistent abdominal pain (pancreatitis concern), unusual fatigue (liver or thyroid), swelling or changes in urination (kidney), or rapid heart rate (thyroid)
Primary endpoint in expanded populations and high-risk subgroups Semaglutide versus sitagliptin Among patients with obesity and type 2 diabetes at low, moderate or high cardiovascular risk in clinical practice, the 1-year risk of the composite endpoint of myocardial infarction or stroke was 1.5% (95% CI 1.4% to 1.6%) with semaglutide compared to 1.7% (95% CI 1.6% to 1.9%) with sitagliptin
Readers should consult their healthcare professional or pharmacist for the most current information on medication availability and treatment options.